Brief: Kiora Pharmaceuticals Says For 2023, Goal Is To Attract Required Capital To Invest Across Three Planned Clinical Trials For Kio-301, Kio-201 And Kio-101
23/03/2023 11:29
March 23 (Reuters) - Kiora Pharmaceuticals Inc KPRX.O :
* KIORA PHARMACEUTICALS - FOR 2023, GOAL IS TO ATTRACT
REQUIRED
CAPITAL TO INVEST ACROSS THREE PLANNED CLINICAL TRIALS FOR
KIO-301, KIO-201 AND KIO-101
Source: [ID: https://bit.ly/42xCb7f]
Further company coverage: KPRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kiora Pharmaceuticals
See all newsKiora Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Kiora Pharmaceuticals, Inc. expected to post a loss of 62 cents a share - Earnings Preview
Brief: Kiora Pharmaceuticals Inc - Enters Securities Purchase Agreement On April 3, 2026 - SEC Filing
Kiora Pharmaceuticals posts 2025 net loss as expenses rise
Brief: Kiora Pharmaceuticals Files For Mixed Shelf Offering Of Up To $100 Million- SEC Filing